SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services. The company was founded in April 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending on news that it became the first national bank to go live with stablecoin settlement across Mastercard's global payments network, with SoFiUSD used for settlement and Galileo clients among the first offered access. The announcement sparked a pre-market rally of roughly 4%, and bulls called it a massive, reputationally significant win for the company's crypto-enabled banking strategy, with some speculating about a short squeeze given a cited ~14% short interest and even suggesting Mastercard could buy the company outright. A vocal bear camp countered by urging traders to short the pre-market pop, pointing to the ticker's recurring pattern of green pre-market sessions fading red at the open, its history of selling off good news, and doubts about whether the partnership justifies the size of the move. Broader frustration from long-term holders over dead money, dilution fears, and underperformance versus peers runs throughout the discussion.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is drawing heavy attention after the company reported positive topline results from a VK2735 weight-loss maintenance study. Traders cite roughly 97% weight-loss maintenance within the trial's 5% threshold, weight loss matching Eli Lilly's retatrutide at the 21- and 33-week marks, and what they describe as a best-in-industry side-effect profile. The company characterized the dose-ranging data as demonstrating the potential viability of novel extended-dosing approaches for maintenance following incretin-based induction.

The reaction is split. Bulls argue the results confirm a best-in-class obesity asset, point to a market cap of roughly $4B as leaving the stock undervalued, and see heavy short interest  one trader citing about 22 million shares short  as fuel for a squeeze. Skeptics counter that maintenance patients almost always regain some weight, that low oral bioavailability limits the oral formulation's dosing, and that other positive obesity readouts have produced lackluster stock reactions; self-identified shorts expect the move to fade. A competing explanation ties the move more to Novo Nordisk's turmoil than to the data itself.

M&A speculation is running alongside the results: traders are floating a Novo Nordisk partnership or a large buyout of Viking after Novo's CEO said the company is 'quite interested' in deals that fill pipeline gaps and that its balance sheet could support larger acquisitions than typical bolt-ons, though others read Novo's messaging as a signal it will not pursue Viking. Many participants stress that the Phase 3 VK2735 readouts  from a program with roughly 5,500 patients enrolled  remain the decisive catalyst.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending ahead of its upcoming earnings report as investors react to a new partnership with Sift to stream sensor data for Physical AI systems. Community sentiment is largely bullish, with traders emphasizing QNX's role in the software-defined vehicle and robotics sectors, though some maintain a cautious stance awaiting a blowout performance to confirm a sustained share price re-rating.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft's formalization of AI safety rules is driving the conversation. The company has unveiled a draft AI code of conduct that would require its future in-house models to accept correction, never resist shutdown, and communicate intelligibly with humans  a move traders frame as part of a broader industry debate over slowing AI development, alongside commentary from Meta and OpenAI. Reaction is split: some see the codification of human-control requirements at the model level as a positive for enterprise trust, while a vocal portion of the community is skeptical, speculating the safety push is a cover for cost concerns rather than genuine ethics. That skepticism feeds a parallel spending debate  traders point to Foundry's substantial losses, claims that AI capex is being funded through borrowing rather than cash flow, and data-center energy constraints as risks to the AI growth narrative. The debate is also surfacing in analyst actions, with Redburn raising its target to $440 and Citizens reiterating a $550 Market Outperform explicitly on the AI safety debate, though some traders argue the stock won't re-rate until earnings momentum and free-cash-flow growth justify the upgrades.

Xanadu Quantum Technologies Ltd. engages in the provision of quantum computing solutions for enterprise and government customers. The company was founded by Christian Weedbrook on October 2, 2025 and is headquartered in Toronto, Canada.

Xanadu Quantum Technologies Ltd. - Ordinary Shares - Class B (Sub Voting)

XNDU is drawing heavy attention amid a standoff between short sellers and bulls, with traders debating why the photonic quantum computing stock isn't flying despite a string of partnership announcements. Bears call it an easy short  citing claimed short interest as high as 68% of the float and an upcoming share unlock  and dismiss the news flow, including a Lockheed Martin quantum collaboration, an ASML deal targeting optical loss, and a Mitsubishi Chemical semiconductor research partnership, as non-revenue headlines, with the Mitsubishi deal pegged at only about $800K. Bulls counter that photonics is the future of quantum computing, tout the Lockheed Martin defense tie-up and a photonic chip packaging milestone, and see the small float as squeeze potential. The company's early-stage, unprofitable profile and steep slide from SPAC-era highs in the $40s to the low $10s fuel the skepticism, while traders also watch whether Xanadu can secure a reported C$300M+ Canadian government grant that some say the market is pricing as unlikely. Broader market weakness and mixed performance across quantum peers add to the debate.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is drawing heavy attention after a Form 4 filing disclosed that CEO Ryan Cohen purchased more than a million shares in another sizable open-market buy, his second major purchase in recent weeks, with directors also adding to their stakes in what traders see as a cluster-buying pattern. Retail sentiment is largely bullish, with many speculating Cohen is positioning ahead of a short squeeze, a potential take-private, or momentum toward the warrant strike price, while skeptics point to the muted price reaction and some are positioning short.

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopify's Q2 earnings beat is dominating the conversation, with traders citing revenue of $3.58B versus roughly $3.44B consensus (34% growth), GMV of $115.57B, and stronger-than-expected Q3 guidance that they say eased fears of AI-driven disruption  the resulting surge marked the stock's biggest intraday gain since November 2024. The dominant debate is whether AI helps or kills the business: bulls point to Bernstein's outperform initiation with a $160 price target and argue AI-disintermediation risk is overdone, while bears are openly shorting the name as a "dying company," warning AI website-building tools will erode Shopify's moat and that the ~$160B market cap leaves little room for error; short-squeeze chatter is circulating amid the fight. Skeptics also question earnings quality, speculating the beat leaned on buybacks and unrealized gains rather than core operations, and traders are split on whether the move holds, watching technical levels like the 21-day moving average for confirmation.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

A wave of Eli Lilly obesity/GLP-1 franchise news is driving the conversation, headlined by its roughly $2.85B acquisition of Merida Biosciences tied to Phase 1b data for the MER511 program. Traders are also weighing new Phase 3b Taltz-plus-Zepbound data, a cardiovascular label update for Mounjaro, UK authorization of Lilly's oral GLP-1 obesity pill, fresh retatrutide (Foundayo) data ahead of a European presentation, and a study linking Zepbound use to lower healthcare costs in adults over 55. Reaction is mixed: some call the stock's pullback an over-reaction to the Merida deal, while others attribute the weakness to broad market and healthcare-sector softness plus profit-taking rather than fundamentals. A recurring debate argues Lilly and Novo Nordisk are competing in an under-penetrated, expanding obesity market rather than a fixed pool of patients - "never short the GLP-1 market" - though some posts flag rising competition from Viking's oral candidate. Speculation about a stock split following a strong earnings report, chatter around the company's $1 trillion market-cap milestone, and possible Lilly buyouts of smaller biotechs also circulate.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

ZETA is trending as the stock pushes through fresh 52-week highs and trades around the heavily watched $30 level, which the community treats as a key psychological barrier. Bulls frame the move around fundamentals they cite from company disclosures  roughly $1.5B in cash and short-term investments, $545M of first-half operating cash flow, and a guidance raise of $33M at the midpoint  along with a widely shared CalSTRS filing showing the pension fund increased its stake more than 1,800% from the prior quarter, which some traders call the '+$30 catalyst.' Attention is also building toward the ZETA Live event and Q3 earnings, with management commentary from Goldman Sachs and Citi conferences cited as evidence that AI adoption and partnerships are accelerating. The bearish side is thinner but present: some traders expect a pullback toward the mid-$20s, and a small secondary offering of roughly 818,000 shares drew debate, though bulls dismissed it as immaterial. References to the prior Culper Research short report still circulate, mostly from traders gloating over short positions getting squeezed.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

The iPhone 18 Pro's in-store launch is dominating the conversation, with traders split between bullish demand signals  long store lines and sellouts in China and Asia  and bearish counters such as shorter delivery wait times suggesting softer early interest. Analyst price-target raises on a better-than-expected refresh cycle are fueling optimism as the stock pushes toward record highs, while skeptics flag the stretched valuation and await the foldable iPhone Duo's debut.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$LXRX + $NVO  
$VTRS  
Now, new research hints that the blockbuster drugs might have yet another benefit: slowing aging. Giving semaglutide to elderly female mice extended their life spans while blunting several cellular hallmarks of getting old, according to a study published in the journal Nature on September 2. 
“Because the GLP-1 medicines reduce food intake, it’s sort of natural for us to ask if GLP-1 medicines actually function as calorie-restriction mimetics to slow aging and extend life span,” she tells Chemical and Engineering News’ Laurel Oldach. 
 
To test this hypothesis, Chen and colleagues injected 20-month-old female mice—roughly equivalent to 60-year-old women—with semaglutide every day for the rest of their lives, while a control group received saline shots. The median life span of saline-treated mice was 742 days, while that of semaglutide-treated mice was 834 days, a 12 percent increase. 
https://www.smithsonianmag.com/smart-news/GLP-1-weight-loss-drugs-can-slow-aging-and-extend-lifespan-mouse-study-suggests-180989452/

nomada

Stefano Pitucci

Craig

Will

Afroze Mohammed

Melissa Gucfa

Older female mice-equivalent in age to 60-year-old women-given daily injections of the active ingredient in Ozempic lived about 12 percent longer than animals that didn't receive the drug

Smithsonian Magazine

GLP-1 Weight-Loss Drugs Can Slow Aging and Extend Life Span, Mouse Study Suggests

StockTwits Web

Lexicon Pharmaceuticals Inc

Novo Nordisk A/S

Viatris Inc

  
Now, new research hints that the blockbuster drugs might have yet another benefit: slowing aging. Giving semaglutide to elderly female mice extended their life spans while blunting several cellular hallmarks of getting old, according to a study published in the journal Nature on September 2. 
“Because the GLP-1 medicines reduce food intake, it’s sort of natural for us to ask if GLP-1 medicines actually function as calorie-restriction mimetics to slow aging and extend life span,” she tells Chemical and Engineering News’ Laurel Oldach. 
 
To test this hypothesis, Chen and colleagues injected 20-month-old female mice—roughly equivalent to 60-year-old women—with semaglutide every day for the rest of their lives, while a control group received saline shots. The median life span of saline-treated mice was 742 days, while that of semaglutide-treated mice was 834 days, a 12 percent increase. 
